CRISPR Therapeutics AG $CRSP Shares Bought by Quantinno Capital Management LP

Posted by Brenda Bartman on Aug 11th, 2026

Quantinno Capital Management LP lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 613.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,989 shares of the company’s stock after purchasing an additional 41,263 shares during the period. Quantinno Capital Management LP’s holdings in CRISPR Therapeutics were worth $2,283,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Mcguire Capital Advisors Inc. acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. acquired a new position in CRISPR Therapeutics in the fourth quarter worth approximately $26,000. Rothschild Investment LLC increased its holdings in shares of CRISPR Therapeutics by 836.7% in the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares in the last quarter. Oakworth Capital Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $34,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth $37,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Trading Down 0.0%

Shares of NASDAQ CRSP opened at $53.51 on Tuesday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48. The business has a 50-day moving average price of $52.36 and a two-hundred day moving average price of $52.31. The firm has a market capitalization of $5.17 billion, a PE ratio of -11.24 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The business had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. As a group, analysts predict that CRISPR Therapeutics AG will post -4.53 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,786 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the transaction, the insider owned 19,357 shares in the company, valued at approximately $1,076,636.34. This represents a 16.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CRSP shares. UBS Group set a $80.00 target price on CRISPR Therapeutics in a report on Friday, June 12th. Wall Street Zen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Evercore reaffirmed an “outperform” rating and set a $76.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, July 8th. Finally, Sanford C. Bernstein lifted their target price on shares of CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.06.

View Our Latest Stock Report on CRISPR Therapeutics

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.